Fenofibrate Enhances the In Vitro Differentiation of Foxp3+ Regulatory T Cells in Mice by Zhou, Zhou et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2012, Article ID 529035, 10 pages
doi:10.1155/2012/529035
Research Article
Fenoﬁbrate EnhancestheInVitro Differentiation of
Foxp3+ RegulatoryTCellsinMice
Zhou Zhou,YingLiang,YanxiangGao,WeiKong, Juan Feng,andXianWang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University Health Science Center,
Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing 100191, China
Correspondence should be addressed to Juan Feng, juanfeng@bjmu.edu.cn and Xian Wang, xwang@bjmu.edu.cn
Received 8 September 2011; Revised 28 November 2011; Accepted 16 December 2011
Academic Editor: Ulrich Kintscher
Copyright © 2012 Zhou Zhou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Foxp3
+ regulatory T cells (Tregs) play a critical role in maintaining immune self-tolerance. Reduced number and activity of
Tregs are usually found in autoimmune and inﬂammatory diseases, and enhancing the diﬀerentiation of Tregs may be a
promising therapeutic strategy. Some reports suggested an anti-inﬂammatory and anti-autoimmune potential for fenoﬁbrate,
a hypolipidemic drug used worldwide, whose lipid eﬀects are mediated by the activation of peroxisome proliferator-activated
receptor α(PPARα). In thepresent paper, we found that fenoﬁbrate dose-dependently increased transforminggrowth factor-β and
interleukin-2-induced Treg diﬀerentiation in vitro, by 1.96-fold from 0 to 20μM (12.59±1.34% to 24.69±3.03%, P<0.05). Other
PPARα activators, WY14643 (100μM ) ,g e m ﬁ b r o z i l( 5 0μM), and bezaﬁbrate (30μM), could not enhance Treg diﬀerentiation. In
addition, PPARα could not upregulate the promoter activity of the Treg-speciﬁc transcription factor Foxp3. Fenoﬁbrate might
exert its function by enhancing Smad3 phosphorylation, a critical signal in Treg diﬀerentiation, via Akt suppression. Our work
reveals a new PPARα independent anti-inﬂammatory mechanism of fenoﬁbrate in up-regulating mouse Treg diﬀerentiation.
1.Introduction
The immune function is normally delicately regulated to
maintain both host defense and self-tolerance. Apart from
negative selection in the process of T-cell development,
recently discovered Foxp3+ regulatory T cells (Tregs) rep-
resent another important aspect in preventing self-immune
reaction [1]. Tregs are a unique group of T cells that mainly
suppress immune reaction and inﬂammation caused by
other immune cells [1]. The dysfunction and reduction
in number of Tregs are found in many autoimmune and
inﬂammatory diseases such as multiple sclerosis, inﬂamma-
tory bowel diseases, type 1 diabetes, rheumatoid arthritis,
systemic lupus erythematosus, psoriasis [2], and atheroscle-
rosis [3]. Enhancing the Treg amount may be a promising
therapeutic target for these diseases.
Atherosclerosis is widely known as a chronic inﬂam-
matory disease with the malfunction of multiple subsets of
immune cells [4, 5]. We and others have revealed a reduced
Treg number involved in deteriorated atherosclerosis [3, 6].
As a widely used lipid-lowering anti-atherosclerosis drug
[7], fenoﬁbrate, a peroxisome proliferator-activated receptor
α (PPARα) activator, has been intensely studied. PPARα-
dependent and -independent anti-inﬂammatory activities
were reported to play an important role in the func-
tion of fenoﬁbrate, such as inhibiting NF-κBa c t i v i t yi n
inﬂammation-related cells [7, 8]. As well, fenoﬁbrate might
modulate the diﬀerentiation of T helper type 1 (Th1) cells
and Th2 cells [9, 10]. However, whether and how fenoﬁbrate
aﬀects the diﬀerentiation of Tregs is still elusive.
Diﬀerentiation is the core process in regulating Treg
amount. Tregs can be diﬀerentiated from na¨ ıve T cells in
the periphery with the induction of transforming growth
factor-β (TGF-β) and interleukin-2 (IL-2) [11, 12]. Long
term phosphorylation of Smad3, the downstream signal of
TGF-β, is the key signal inducing the transcription factor
Foxp3 [13], upon which the diﬀerentiation of Tregs commits
[14].Althoughseveralfactors,suchasAktactivation[15,16],
may inhibit Treg diﬀerentiation, clinical drugs targeting this
process are still limited.
In the present study, we found that fenoﬁbrate improved
the diﬀerentiation of Foxp3+ Treg cells induced with TGF-β2 PPAR Research
and IL-2 in vitro, which might be associated with reduced
Akt phosphorylation and enhanced long-term activation
of Smad3. Other PPARα activators, including bezaﬁbrate,
gemﬁbrozil, and WY14643, did not show the same activity as
fenoﬁbrate, so this Treg diﬀerentiation-improving function
might be speciﬁc to fenoﬁbrate and independent of PPARα
activation.
2.MaterialsandMethods
2.1. Cell Sorting. Six-week-old special pathogen-free female
C57BL/6 mice were provided by the Animal Center of Peking
UniversityHealthScienceCenter(Beijing,China).Thisstudy
was carried out in accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals
of the Health Science Center of Peking University. The
protocol was approved by the Committee on the Ethics of
Animal Experiments of the Health Science Center of Peking
University. All surgery was performed with mice under
sodium pentobarbital anesthesia, and all eﬀorts were made
tominimize suﬀering.Aftermicewerekilled,totalandCD4+
Tcellsofmousespleenswereenrichedwithpositiveselection
magnetic microbeads against CD90.2 and CD4, respectively
(Miltenyi Biotec, Bergisch Gladbach, Germany), following
the manufacturer’s instructions.
2.2. Cell Culture and Induction of Treg Diﬀerentiation In
Vitro. Total and CD4+ T cells were puriﬁed and cultured
as described [17] with minor modiﬁcation. Brieﬂy, 1 ×
106 total or CD4+ T cells were cultured with RPMI 1640
medium (Hyclone, Carlsbad, CA, USA) containing 10%
fetal bovine serum (Hyclone) in each well of 48-well plates
containing plate-bound anti-CD3 (1μg/mL, BD Pharmagen,
Franklin Lakes, NJ, USA) and soluble anti-CD28 (1μg/mL,
BDPharmagen)antibodies.ForTregdiﬀerentiation,cultures
were supplemented with 5ng/mL TGF-β1( P e p r oT e c h ,
Rocky Hill, CT, USA) and 50U/mL IL-2 (R&D Systems,
Minneapolis, MN, USA). Anti-interferon- (IFN-) γ antibody
(5μg/mL) and anti-IL-4 antibody (5μg/mL, both R&D
Systems) were added as indicated. Fenoﬁbrate, WY14643,
bezaﬁbrate, and gemﬁbrozil (all from Sigma Chemical, St.
Louis, MO, USA) were used at the doses indicated. For ﬂow
cytometry and RT-PCR, cells were collected 4 days later. For
westernblot analysis,cellswerecollected24 or 48hours later.
2.3. Flow Cytometry. For Foxp3 staining, cells were collected
and stained with FITC or APC-tagged anti-Foxp3 antibody
(eBioscience, San Diego, CA). For CD4, CD8, and Foxp3
multiple staining, cells were stained with FITC-tagged CD4
antibody and PE-tagged CD8 antibody (eBioscience), then
with APC-tagged anti-Foxp3 antibody according to the
manufacturer’s instructions. Stained cells were analyzed by
FACScan ﬂow cytometry with Cell QuestPro software (BD
Biosciences, USA).
2.4. Real-Time RT-PCR Analysis. Cells were collected 4 days
after the initiation of Treg cell diﬀerentiation. RNA isolation
and real-time RT-PCR were performed as described [18].
Brieﬂy, total RNA was extracted by the TRIzol reagent
method(Invitrogen,Carlsbad,CA,USA).Onemicrogramof
total RNA per sample was reverse-transcribed with use of the
AMVReverseTranscriptionSystem(Promega,Madison,WI,
USA). Real-time PCR ampliﬁcations involved an Mx3000
Multiplex Quantitative PCR System (Stratagene Corp, La
Jolla, CA, USA) and SYBR Green I reagent.
All ampliﬁcation reactions were carried out for 40 cycles
(an initial stage of 7min at 95◦C, followed by a three-step
cycle of 20s at 94◦C, 25s at 60◦C, and 30s at 72◦C) and
were performed in duplicate. The accuracy of PCR products
was conﬁrmed by sequencing amplicons. The relative target
mRNA levels were assessed with use of Stratagene Mx3000
software and normalized to that of the internal control, β-
actin. The primers were for Foxp3, forward, TCCTTCCCA-
GAGTTCTTCCAC and reverse, ACTTGTGCAGGCTCA-
GGTTGT; β-actin, forward, ATCTGGCACCACACCTTC
and reverse, AGCCAGGTCCAGACGCA.
2.5. Western Blot Analysis. Immunoblotting was performed
as described [18]. Brieﬂy, T cell lysis samples containing
the same amount of protein were resolved on 10% SDS-
PAGE. The membranes were incubated with primary anti-
bodies and then IRDye 800DX- or IRDye 700DX-conjugated
secondary antibodies (Rockland, Gilbertsville, PA, USA).
The immunoﬂuorescence signal was detected by use of
the Odyssey infrared imaging system (LICOR Biosciences,
Lincoln, NB, USA). The primary antibodies included anti-
phosphorylated-STAT5, anti-total and phosphorylated-Akt,
anti-total-Smad3, anti-β-actin antibodies (all from Cell Sig-
nal Technology, Danvers, MA, USA), anti-phosphorylated-
Smad3 antibody (Millipore, Billerica, MA, USA), anti-total-
STAT5, and anti-eIF5 antibodies (both from Santa Cruz
Biotechnology, CA, USA).
2.6. Transfection and Luciferase Reporter Assay. Transfection
and luciferase reporter assays were performed as described
[19] with minor modiﬁcation. Brieﬂy, mouse embryonic
ﬁbroblastcellsorHEK293Acellsweretransfectedwith0.1μg
Foxp3 promoter reporter plasmid or 0.1μgp e r o x i s o m e
proliferator response element (PPRE) luciferase reporter
plasmid, together with β-galactosidase-expressing plasmid
as an internal reference with use of cationic polymer
transfectionreagent(JetPEI, France),aswellas0.2μgPP ARα
plasmid if indicated, or 0.2μg control plasmid GFP. After
transfection for 4 hours, the cells were incubated with fresh
Dulbecco modiﬁed Eagle medium (DMEM) containing 10%
fetal bovine serum and fenoﬁbrate, gemﬁbrozil, WY14643,
bezaﬁbrate, phorbol 12-myristate 13-acetate (PMA) plus
ionomycin, or solute control, respectively. 24hours later, the
growth medium was removed and replaced with 200μLo f
reporter lysis buﬀer and the luciferase and β-galactosidase
activity was measured with use of a luciferase assay system
(Promega, Madison, WI, USA).
2.7. Statistical Analysis. All data are expressed as mean ±
SEM or original data representing 1 of at least 3 independent
experiments. Unpaired Student t test was used to comparePPAR Research 3
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Figure 1: Fenoﬁbrate promoted the diﬀerentiation of Tregs in vitro. Total T cells (a) or CD4+ T cells (d) were isolated from mouse spleens
and induced to diﬀerentiate into Tregs with 5ng/mL TGF-β, 50U/mL IL-2, and fenoﬁbrate doses indicated. The percentage of Foxp3+ T
cells was analyzed by ﬂow cytometry 4 days later. The mRNA level of Foxp3 in total T cells was analyzed by real-time PCR (b), and the
percentages of Foxp3+ T cells in CD4+ and CD8+ T cell subgroups were analyzed by ﬂow cytometry (c). In (a) and (d), numbers in the upper
right corner indicate the ﬁnal concentration of fenoﬁbrate, and the outlined areas indicate Foxp3+ T cells with percentages shown in the
lower right corner, n =5∼6, ∗P<0.05 versus 0μMg r o u p .I n( b )n = 4, ∗P<0.05 versus 0μM group. In (c) data represent 1 of at least 3
independent experiments.
2 groups and one-way ANOVA followed by Newman-Keul
post-hoc test to compare multiple groups. P<0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Fenoﬁbrate Enhanced the Diﬀerentiation of Tregs In Vitro.
To determine the eﬀect of fenoﬁbrate on the diﬀerentiation
of Tregs, we induced Treg diﬀerentiation in vitro with
TGF-β and IL-2. Fenoﬁbrate (10∼20μM) dose-dependently
potentiated the ratio of diﬀerentiated Foxp3+ Tc e l l st o
total T cells after 4-day induction. An amount of 20μM
fenoﬁbrate elevated the Foxp3+ cell percentage by 2.12-fold,
from 8.72±0.95% to 18.51±1.21% (P<0.05) (Figure 1(a)).
The mRNA level of Foxp3 was increased accordant with
enhanced Treg diﬀerentiation by fenoﬁbrate (Figure 1(b)).
The live cell ratio was approximately 70% in all the groups
(datanotshown).CD4+ andCD8+ Tcellswerebothinduced
to express Foxp3 by TGF-β and IL-2, with most being CD4+
T cells. Fenoﬁbrate elevated the percentage of Foxp3+ cells
from both cell subgroups (Figure 1(c)), which suggests that
the eﬀect of fenoﬁbrate is not restricted to CD4+ or CD8+
T cells. In addition, Treg diﬀerentiation from puriﬁed CD4+
T cells was also improved dose-dependently by fenoﬁbrate.
FenoﬁbratepromotedtheTregdiﬀerentiation 1.96-foldfrom
12.59±1.34% to 24.69±3.03% at 20μM( P<0.05) in CD4+
T cells (Figure 1(d)). These data suggest that fenoﬁbrate
improves the diﬀerentiation of Treg cells in vitro.
3.2. IFN-γ a n dI L - 4W e r eN o tI n v o l v e di nt h eE ﬀect of
Fenoﬁbrate on Treg Diﬀerentiation. Previousstudiesreported
that fenoﬁbrate could reduce the expression of IFN-γ and
enhance the expression of IL-4 from activated T cells [9, 10].
Because these 2 cytokines were both shown to inhibit Treg
diﬀerentiation, we examined whether fenoﬁbrate exerted
its function by interfering with the secretion of IFN-γ
and IL-4. Anti-IFN-γ and anti-IL-4 neutralizing antibodies
were supplemented in the Treg diﬀerentiation system, but
fenoﬁbrate could still up-regulate the rate of diﬀerentiated
Foxp3+ T cells from total T cells and puriﬁed CD4+
T cells (Figure 2). Therefore, fenoﬁbrate enhanced Treg
diﬀerentiation independent of IFN-γ or IL-4.
3.3. PPARα Activation Was Not Involved in the Function of
Fenoﬁbrate. Because fenoﬁbrate is well known as a recombi-
nant PPARα activator, we next checked whether fenoﬁbrate
exerted its Treg-diﬀerentiation stimulating function through
PPARα. First, we examined whether fenoﬁbrate shared a
similar function with other PPARα activators. Three other
PPARαactivators,100μMWY14643,50μMgemﬁbrozil,and
30μM bezaﬁbrate (Figures 3(a), 3(b),a n d3(c),r e s p . )w e r e
added to the Treg diﬀerentiation system, but none of them
up-regulated the diﬀerentiation of Treg cells induced with
TGF-β and IL-2.
To further examine whether PPARα activation mod-
ulated the expression of Foxp3, we tested whether the
promoter activity of Foxp3 could be improved by fenoﬁbratePPAR Research 5
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Figure 2: The eﬀect of fenoﬁbrate on Tregs did not involve changes in IFN-γ and IL-4 expression. Total T cells (a) and CD4+ Tc e l l s( b )
were isolated from mouse spleens and induced to diﬀerentiate into Tregs with 5ng/mL TGF-β,5 0U / m LI L - 2 ,5μg/mL IFN-γ neutralizing
antibody, 5μg/mL IL-4 neutralizing antibody, and fenoﬁbrate doses indicated. After 4 days of induction, the percentage of Foxp3+ Tc e l l s
was analyzed by ﬂow cytometry. Numbers in the upper right corner indicate the ﬁnal concentration of fenoﬁbrate, and the outlined areas
indicate Foxp3+ T cells with percentages shown in the lower right corner. Data represent 1 of at least 3 independent experiments.
or PPARα over-expression. We constructed the luciferase
reporter of Foxp3 promoter and transfected it into mouse
embryonic ﬁbroblast (MEF) cells. The luciferase activity was
not aﬀected by the stimulation of 20μMf e n o ﬁ b r a t eo rf u r -
therexpressionofPPARα(Figure4(a)).TheeﬃcacyofFoxp3
promoter was tested by the stimulating eﬀect of 50ng/mL
PMA and 1μg/mL ionomycin (Figure 4(b)). The eﬃciency
of PPARα expression and activation was conﬁrmed by the
activation of thePPREluciferasereporter (Figures 4(c),4(d),
and, see supplemental ﬁgure, in supplementary material
available online at doi: 10.1155/2012/529035). These data
suggest that Foxp3 promoter activity could not be inﬂuenced
by PPARα,a n dP P A R α activation might not be involved in
fenoﬁbrate-enhanced Treg diﬀerentiation.
3.4. Fenoﬁbrate Improved the Phosphorylation of Smad3.
We next investigated the mechanism of the fenoﬁbrate
eﬀect on Treg diﬀerentiation. TGF-β and IL-2 are 2 major
cytokines that induce the diﬀerentiation of Tregs [17], so
we checked whether fenoﬁbrate regulated their signals. Long
term activation of Smad3, downstream of TGF-β, is a critical
signal in enhancing the diﬀerentiation of Tregs [20, 21].
In our study, phosphorylation of Smad3 was signiﬁcantly
up-regulated by fenoﬁbrate 48 hours after the induction,
with only slight eﬀe c ta t2 4 h o u r s( F i g u r e5(a)). However,
phosphorylation of STAT5, the downstream signal of IL-2,
was not aﬀected by fenoﬁbrate (Figure 5(b)). These data
indicate that enhancing the TGF-β signal might be a critical
step in improving Treg diﬀerentiation by fenoﬁbrate, and the
IL-2 signal might not take a major part.
3.5. Fenoﬁbrate Suppressed the Activation of Akt. Akt activa-
tion is an important inhibitory signal for Treg diﬀerentiation
[15,16].Aswell,activatedAktcanblockthephosphorylation
ofSmad3bytheTGF-β receptor complex [22].WefoundAkt
activation signiﬁcantly inhibited by fenoﬁbrate 24 hours and
48 hours after Treg induction (Figure 6(a)). Furthermore,
an Akt signal blocker, LY294002, suﬃciently improved
Treg diﬀerentiation, conﬁrming the inhibitory eﬀect of Akt
signal on Treg diﬀerentiation. Moreover, in the presence
of LY294002, fenoﬁbrate could not further enhance Treg
diﬀerentiation (Figure 6(b)). Thus, fenoﬁbrate probably
enhanced Smad3 activation and then Treg diﬀerentiation
at least in part by suppressing the phosphorylation of Akt,
which was important in its very function.6 PPAR Research
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Figure 3: WY14643, gemﬁbrozil, and bezaﬁbrate did not aﬀect Treg diﬀerentiation in vitro. Total and CD4+ T cells were isolated from
mouse spleens and induced to diﬀerentiate into Treg cells with 5ng/mL TGF-β and 50U/mL IL-2. 100μM WY14643 (a), 50μM gemﬁbrozil
(b) and 30μM bezaﬁbrate (c) or solute control were added respectively. 4 days later the percentage of Foxp3+ T cells was analyzed with ﬂow
cytometry. The outlined areas indicate Foxp3+ T cells, and the percentages were shown in the lower right corner. Data represent 1 of at least
3 independent experiments.
4. Discussion
Regulatory T cells are a recently discovered T cell subgroup
that plays a critical role in maintaining immune self-
tolerance and controlling immune activity [1]. Modulating
the diﬀerentiation of Treg cells may be a promising thera-
peutictargetfortreatingautoimmuneandinﬂammatorydis-
eases[2].However,artiﬁcialexogenouschemicalcompounds
improving Tregdiﬀerentiation arestill limited. Inthe present
study, we found that a hypolipidemic drug, fenoﬁbrate,
enhanced the diﬀerentiation of Tregs induced by TGF-β and
IL-2 in vitro, probably by inhibiting Akt activation and thenPPAR Research 7
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Figure 4: PPARα activation could not improve Foxp3 promoter activity. (a) MEF cells were transfected with Foxp3 promoter-luciferase
reporter plasmid along with β-galactosidase plasmid, then stimulated with 20μM fenoﬁbrate or further transfected with PPARα plasmid.
All groups received equal amount of solute and plasmid adjusted with ethanol and GFP plasmid. (b) Foxp3 promoter-luciferase reporter
plasmid and β-galactosidase plasmid were transfected into MEF cells and then the cells were stimulated with 50ng/mL PMA and 1μg/mL
ionomycin. PPRE-luciferase reporter plasmid and β-galactosidase plasmid were transfected to MEF cells with PPARα expression plasmid or
equal amount of GFP control plasmid (c) or to HEK 293 cells that were immediately stimulated with 20μM fenoﬁbrate, 50μM gemﬁbrozil
or 100μM WY14643 (d). 24hours later, luciferase activity relative to β-galactosidase activity was analyzed. n = 5, ∗P<0.05.
enhancing the TGF-β signal, Smad3 phosphorylation. Our
study might provide information on a new promising drug
for treating autoimmune and inﬂammatory diseases.
Retinoic acid [23] and 2,3,7,8-tetrachlorodibenzo-p-
dioxin [24] were previously found to improve the diﬀer-
entiation of Treg cells in vivo and in vitro. Both of these
chemicals are ligands of nuclear receptors, retinoic acid
receptor and aryl hydrocarbon receptor, respectively, and
their activation of the receptors was key to improving Treg
diﬀerentiation [23, 24]. However, we found that fenoﬁbrate,
as a chemical ligand of nuclear receptor PPARα [7], exerted
its eﬀect on Treg diﬀerentiation probably independent of
PPARα activation. We and others showed that PPARα
activation could not enhance the promoter activity of the
Treg-speciﬁc transcription factor Foxp3 [25]. Also, other
PPARα activators, WY14643, gemﬁbrozil, and bezaﬁbrate,
could not aﬀect Treg diﬀerentiation. So fenoﬁbrate might be
a unique member of the PPARα ligands in regulating Treg
diﬀerentiation.
Long-term Smad3 activation is a critical signal inducing
the expression of Foxp3 and then Treg diﬀerentiation. The
positive eﬀect of retinoic acid [20]a n dS 1 P 1 blockers [21]
on the diﬀerentiation of Treg cells were both at least in
part due to enhancing long term Smad3 phosphorylation.
In our study, we for the ﬁrst time in the world revealed
thatfenoﬁbrateenhancedSmad3activationbyTGF-β,which
might explain its eﬀect on Treg diﬀerentiation. In contrast
to Smad3, Akt activation is an important endogenous sup-
pressive signal for Treg diﬀerentiation [15, 16]. Although the
inhibitory eﬀect of fenoﬁbrate on Akt activation was recently
found outside the immune system [26], we have supplied
the ﬁrst evidence that fenoﬁbrate could also suppress Akt
phosphorylationinTcells.ActivatedAktcanblockthesignal
transduction from the activated TGF-β receptor complex to
Smad3 at the molecular level [22, 27]. Moreover, low level
Akt phosphorylation and high level Smad3 phosphorylation
were also found in the same Treg favoring conditions [21].
So, inhibition of Akt might be an upstream signal of
fenoﬁbrate enhancing Smad3 activation. This Akt, Smad3,
Foxp3 cascade might explain at least in part the positive
eﬀect of fenoﬁbrate on Treg diﬀerentiation. Also, this Akt
suppressing eﬀect might improve Treg diﬀerentiation via
other mechanisms independent of Smad3 enhancement.
Besides the peripheral diﬀerentiation induced by TGF-β
andIL-2,Tregcellscanalsobedirectlyinducedinthethymus
[28]. Whether this thymus Treg diﬀerentiation is modulated8 PPAR Research
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Figure 5: Fenoﬁbrate enhanced Smad3 activation. Total mouse splenic T cells were induced to diﬀerentiate into Treg cells by use of 5ng/mL
TGF-β a n d5 0U / m LI L - 2 ,a n d2 0μM fenoﬁbrate or solute control. 24 and 48hours later, the phosphorylation of Smad3 (a) and STAT5 (b)
as well as the total protein level were examined by western blot analysis. In (a) n = 6, ∗P<0.05 versus solute control group. In (b) data
represent 1 of at least 3 independent experiments.
by fenoﬁbrate and the overall action of the immune system
with fenoﬁbrate-enhanced Treg diﬀerentiation improves
autoimmune and inﬂammatory diseases in vivo remain for
further investigations.
Autoimmune and inﬂammatory diseases are severe dis-
eases for humans, and the current treatments are limited. We
fortheﬁrsttimerevealedthatfenoﬁbratecouldimproveTreg
diﬀerentiation in vitro, with implications for ameliorating
autoimmune and inﬂammatory diseases. To our knowledge,
fenoﬁbrate is the ﬁrst widely used drug to possess this
function. Added to its previously found anti-inﬂammatory
and Th1 diﬀerentiation functions, fenoﬁbrate might be a
safe alternative for treating autoimmune and inﬂammatory
diseases.
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